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The Tobacco Heating System (THS) 2.2, a candidate Modiﬁed Risk Tobacco Product (MRTP), is designed to
heat tobacco without burning it. Tobacco is heated in order to reduce the formation of harmful and
potentially harmful constituents (HPHC), and reduce the consequent exposure, compared with
combustible cigarettes (CC). In this 5-day exposure, controlled, parallel-group, open-label clinical study,
160 smoking, healthy subjects were randomized to three groups and asked to: (1) switch from CCs to THS
2.2 (THS group; 80 participants); (2) continue to use their own non-menthol CC brand (CC group; 41
participants); or (3) to refrain from smoking (smoking abstinence (SA) group; 39 participants). Bio-
markers of exposure, except those associated with nicotine exposure, were signiﬁcantly reduced in the
THS group compared with the CC group, and approached the levels observed in the SA group. Increased
product consumption and total puff volume were reported in the THS group. However, exposure to
nicotine was similar to CC at the end of the conﬁnement period. Reduction in urge-to-smoke was
comparable between the THS and CC groups and THS 2.2 product was well tolerated.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The U.S. Family Smoking Prevention and Tobacco Control Act
(FSPTCA) deﬁnes a Modiﬁed Risk Tobacco Product (MRTP) as “any
tobacco product that is sold or distributed for use to reduce harm or
the risk of tobacco related disease associated with commercially
marketed tobacco products” (Family Smoking Prevention and
Tobacco Control Act). This publication is part of a series of nine
publications describing the nonclinical and part of the clinical
assessment of a candidate MRTP, Tobacco Heating System (THS) 2.2
regular and a mentholated version (THS 2.2M). The series of pub-
lications provides part of the overall scientiﬁc program to assess the
potential for THS 2.2 to be a reduced risk product. The ﬁrst publi-
cation in this series describes THS 2.2 and the assessment program
for MRTPs (Smith et al., 2016). This is followed by six publications,
including this one, that describe the nonclinical assessment of THS
2.2 regular and THS 2.2M (Kogel et al., 2016; Oviedo et al., 2016;
Schaller et al., 2016a,2016b; Sewer et al., 2016; Wong et al., 2016)., Research & Development, 5
ziza).
Inc. This is an open access article uThe eighth publication in the series describes a clinical study to
assess whether the reduced formation of Harmful and Potentially
Harmful Constituents (HPHC) for THS 2.2 regular also leads to
reduced exposure to HPHCs when the product is used in a clinical
setting (Haziza, 2016). A ﬁnal publication utilizes data gathered
from the reduced exposure clinical study on THS 2.2 regular to
determine if a systems pharmacology approach can identify expo-
sure response markers in peripheral blood of smokers switching to
THS 2.2 (Martin et al., 2016).
Novel tobacco products with the potential to reduce exposure to
HPHCs in cigarette smoke, to lower the individual risk of smoking-
related diseases, and lessen population harm compared to smoking
combustible cigarettes (CC), are important components of current
harm reduction strategies. The Tobacco Advisory Group of the Royal
College of Physicians opined that “if nicotine could be delivered
effectively and acceptably to smokers without smoke, most if not all
of the harm of smoking could probably be avoided” (Royal College
of Physicians (2016)). The Tobacco Heating System (THS) 2.2, a
candidate reduced risk product, was developed by Philip Morris
International (PMI) to provide an acceptable alternative to CC
smoking and replicate the ritual, taste, sensory characteristics, and
nicotine uptake of CC smoking.
Such reduced risk products are regulated in the US under thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Drug Administration in 2012, which requires rigorous scientiﬁc
assessment pre-marketing in order to sell a product with a claim to
reduced harm (FDA (Food and Drug Administration), 2012a). THS
2.2 heats the tobacco, rather than burning it, and eliminates com-
bustion to create a far less complex aerosol with lower levels of
HPHCs compared with CCs (Borgerding and Klus, 2005; Forster
et al., 2015). Heated tobacco products, including earlier THS ver-
sions, have been tested in clinical studies in which they reduced
exposure to HPHCs and had favorable effects on early, clinically
relevant risk markers of disease (Roethig et al., 2010; Sakaguchi
et al., 2014; Unverdorben et al., 2010). The ﬁrst version of the THS
(THS 1.0) was launched in limited test markets, namely
Switzerland, Japan, Australia, and Germany between 2006 and
2010. Consumer adoption was poor, mostly because of its bulky
design and shortcomings in its sensory and taste characteristics.
THS 2.2 addressed the shortcomings of THS 1.0 reported by con-
sumers. In addition, the physical and functional characteristics of
THS 2.2 were improved by lowering the temperature of the heating
element to <350 C.
The clinical study reported here aimed to demonstrate a
reduction in exposure to HPHCs.
In this randomized and controlled clinical study, in a conﬁned
setting, we compared the effects of ad libitum use of THS 2.2, CC use,
and smoking abstinence, on the concentrations of biomarkers of
exposure to HPHCs, measured in urine and blood. THS 2.2 and CC
were used without restriction. Dual use of CCs and THS 2.2 was not
allowed. Additional outcomes included the subjective effects of
smoking (product satisfaction, and urge-to-smoke), human pufﬁng
topography (HPT), and safety. This study provides a comprehensive
insight on the maximum possible reduction in exposure to HPHCs
after switching from CC to THS 2.2 and how these reductions
compare to what is achieved when subjects stop smoking for the
same period of time. Biomarkers of exposure were selected based
on a “ﬁt-for-purpose” approach (IOM (Institute of Medicine) 2012)
which provides a reasonable representation of the exposure when
an individual is using THS 2.2 exclusively along with safety
information.
2. Methods
2.1. Participants
Adult Caucasian smokers aged 21e65 years were eligible for
participation in the study. Potential participants were eligible if
they smoked 10 commercially available non-menthol CCs per
day with a maximum yield of 1 mg nicotine per cigarette (ISO
yield) for the last 4 weeks and had smoked CC for  3 consec-
utive years before enrollment. Study participants were recruited
via the clinical site's database and through advertisements.
Before participation in the study, all participants provided writ-
ten informed consent and underwent screening procedures, such
as physical examinations and a medical check-up. Only candi-
dates not willing to quit smoking in the forthcoming 3 months
were allowed in the study, but they had to be ready to accept a 5-
day abstention from smoking. Participants with clinically rele-
vant medical conditions, or who potentially required medical
interventions (start of treatment, surgery, or hospitalization) and
participants with a history of alcohol and/or drug abuse, or who
used nicotineecontaining products other than their own brand of
CC, as well as pregnant or breast-feeding female subjects and
females unwilling to use acceptable methods of effective
contraception, were excluded. All participants were informed
that they were free to withdraw from the study at any time.
Participants willing to quit smoking after enrolment wereencouraged to do so and discontinued. They were also referred to
a smoking cessation counsellor to receive appropriate medical
advice. All participants were compensated for their time and
participation.
2.2. Study design
This study was designed as a controlled, randomized, three-
arm parallel, single-center study in conﬁnement. The Screening
Period covered a maximum of 4 weeks (Day 30 to Day 3) prior
to Admission on Day 2 to the study site. Prior to enrollment on
Day 2, as the last procedure of the eligibility assessments on that
day, all subjects participated in a product trial of THS 2.2 (using up
to three THS 2.2 tobacco sticks). In female subjects, the THS 2.2
product trial was performed only after pregnancy was excluded by
a negative urine pregnancy test. On Day 2, after all inclusion/
exclusion criteria had been met, eligible candidates were enrolled
and conﬁned under medical supervision until Discharge on Day 6.
On Day 1 and Day 0, participants smoked their own preferred
brand of CCs for Baseline assessments. One hundred sixty partic-
ipants were randomized with stratiﬁcation by sex, and average
self-reported daily cigarette consumption over 4 weeks, before
enrollment (10e19 CC vs. >19 CC per day) in a 2:1:1 randomiza-
tion ratio to THS 2.2 use (n ¼ 80), CC smoking (n ¼ 40) or to
abstain from smoking (n ¼ 40) on Day 1 following the two days of
Baseline assessments. From Day 1 to Day 5, participants in the THS
and CC groups used, respectively, THS 2.2 or their own brand of
non-menthol CCs exclusively. Participants in the SA arm were
asked to completely abstain from smoking from Day 1 to Day 5. No
participant was allowed to use any supportive medication for
smoking abstention. On Day 6 or on the day of early discontinu-
ation, end of study procedures were conducted. After discharge on
Day 6, or in case of an early discontinuation, participants entered a
7-day Safety Follow-Up Period for recording of spontaneously
reported new adverse events (AEs), serious adverse events (SAEs),
or follow-up of any ongoing AEs/SAEs that occurred during
conﬁnement (Fig. 1).
From Day 1 to Day 5, for CC, and from Day 1 to Day 5 for THS
2.2, product use was allowed during the designated product use
hours from 06:30 to 23:00 ad libitum, and 24-h urine was collected
on each day. The study was conducted between June and
September 2013 at BioVirtus Research Site (Kajetany, Poland). The
study protocol was approved by the local ethics committee and
adhered to the principles of the Declaration of Helsinki (World
Medical Association (WMA), 2013), Good Clinical Practice guide-
lines (International Conference on Harmonisation, 2014) and na-
tional regulations. The study was registered at www.clinicaltrials.
gov (NCT01959932).
2.3. Investigational products
The THS 2.2 product was developed and provided by Philip
Morris Products S.A. (part of Philip Morris International group of
companies). The product is described in part 1 of this series (Smith
et al., 2016). Brieﬂy, THS 2.2 has three components: the tobacco
stick, the holder, and the charger. The tobacco stick (FR1 blend)
contains a tobacco plug of processed tobacco cast leaf, which is
enclosed in a paper wrap. The overall appearance of the tobacco
stick is similar to a CC, except it is much shorter. The holder includes
a battery, controlling electronics, and the heating element. The
tobacco stick is inserted into the holder, and an electronically
controlled heating blade heats the tobacco according to a carefully
controlled temperature proﬁle to temperatures not exceeding
300 C. The charger recharges the holder.
To use THS 2.2, the tobacco stick is inserted into the holder and
Fig. 1. Study design. Study design schematic representation of the procedures followed by participants. Abbreviations: CC ¼ conventional cigarette use group; THS2.2 ¼ Tobacco
Heating System 2.2 use group.
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the holder. An LED indicates when the initial heating process is
complete. The holder and tobacco stick are designed for a usage
period of approximately 6 minutes or for around 14 puffs. The
holder must be recharged after each usage period of 6 min and a
new tobacco stickmust be used for the next usage cycle. The THS 2.2
test product contained 0.5 mg nicotine as determined under ISO
conditions and 56.4 mg/stick of glycerin as aerosol former. The
mainstream composition of the aerosol of THS 2.2, and its non-
clinical assessment, including neutral red uptake assay, mouse
lymphoma, and Ames assays are presented as part of this series,
including 8 publications (Schaller et al., 2016a,2016b). A reduction
of over 90% for the majority of HPHCs measured, and a decrease in
cytotoxicity and mutagenic potential, was observed when
compared to the 3R4F reference cigarette. The reference product in
this clinical study were the participant's own preferred brand of
non-menthol CCs used in the CC group. CCs were not provided by
the Sponsor, and subjects were asked to buy and bring their own
CCs to the investigational site.2.4. Sample size
The sample size was determined based on the expected least
squares (LS) mean ratios (THS2.2:CC) of the concentrations of
biomarkers of exposure adjusted for creatinine (except for COHb),
as observed in previous studies with heated tobacco products
(ClinicalTrials.gov ID: NCT00812279; ID: NCT01780714). A total of
160 participants were randomized at a ratio of 2:1:1 to the THS, CC,
and SA group respectively, and were considered sufﬁcient to attain
>80% power to show a reduction of 50% in the concentrations of
carboxyhemoglobin (COHb), 3-hydroxypropylmercapturic acid (3-
HPMA), monohydroxybutenyl mercapturic acid (MHBMA), and S-
phenylmercapturic acid (S-PMA) in the THS group relative to the CC
group, with a one-sided probability of 2.5% for type I error. The
overall type I error was preserved by simultaneously testing the
endpoints using a closed procedure.2.5. Statistical analysis
The biomarkers of exposure were analyzed in all randomized
participants who used the allocated product at least once after
randomization and with at least one valid value for a biomarker of
exposure. Statistics were derived for each biomarker of exposure
and the percent change or relative change as compared to baseline
according to study group and study day. Descriptive summary
statistics included the number of participants (n), number and
percent of participants with missing data, arithmetic mean, arith-
metic standard deviation (SD), median, ﬁrst and third quartiles,
minimum, maximum, geometric mean and associated 95% conﬁ-
dence intervals (CI), and geometric coefﬁcient of variation (CV) for
each study group, stratiﬁed by sex and CC use for 4 weeks before
enrollment. Inferential analysis was performed on the endpoints
observed on Day 5.
Inferential analysis was performed on the endpoints related to
the primary objective including S-PMA, MHBMA, COHb, and 3-
HPMA as observed on Day 5. Analysis of covariance was conduct-
ed on log-transformed variables to estimate the ratios between the
study groups (one sided type I error of 2.5%) with adjustment for
sex, CC use over the 4 weeks before enrollment, and the log-
transformed baseline value of the biomarker. The estimated dif-
ferences between the study groups and associated CIs were back-
transformed to provide relative ratio (THS 2.2/CC). A similar sta-
tistical approach was applied for the other endpoints. All statistical
analyses were performed using Statistical Analysis Software (SAS),
version 9.3 (SAS Inc., Cary, NC, USA).2.6. Biomarkers of exposure
Biomarkers of exposure to selected HPHCs were measured
throughout the study from Day1 to Day 5. The HPHCs assessed in
this study were selected based on the following criteria:
1) HPHCs recommended for lowering in cigarette smoke as deﬁned
by the WHO (WHO Study Group et al., 2008) and the draft
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for Tobacco Products (CTP) on “Reporting Harmful and Poten-
tially Harmful Constituents in Tobacco Products and Tobacco
Smoke” (FDA (Food and Drug Administration), 2012b).
2) The HPHC is speciﬁc to cigarette smokewith other sources being
minor or non-existent.
3) The Biomarker of exposure to a HPHC is easily detectable using
validated, reliable, reproducible, and precise analytical methods.
4) The HPHC reﬂects a speciﬁc toxic exposure or is a reliable sur-
rogate of exposure to HPHCs.
5) The list of HPHCs includes HPHCs from both the gas and par-
ticulate phases.
6) The list of HPHCs includes a broad variety of chemical classes
and organ toxicity classes as deﬁned by the FDA (U.S.
Department of Health and Human Services, 2012) (carcinogen,
cardiovascular toxicant, respiratory toxicant, reproductive and
development toxicant, addiction potential).
7) The list of HPHCs includes HPHCs formed at different temper-
ature levels.
8) Most exhibit a variety of elimination half-life times ranging from
a few hours up to more than 2 weeks with the majority of
elimination half-life times below 24 h.
The study included biomarkers of exposure to the tobacco-
speciﬁc HPHCs 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK), and N-nitrosonornicotine (NNN), and the biomarkers of
exposure of the following 4 HPHCs: 1,3-butadiene, acrolein, ben-
zene, carbon monoxide on which study objectives and sample size
were based. In addition to fullﬁlling criteria 1e8, these 4 bio-
markers of exposure were selected as coefﬁcient of variation and
mean ratios between a previous prototype of THS and CC were
available for each of them from a previous study (Lüdicke et al.,
2016). Additionally biomarkers of exposure to other HPHCs were
also included (Table 1). Ammonia was not measured as no known
speciﬁc biomarker of exposure to ammonia exists in humans or
animals and no evidence for alterations in clinical indices of body
ammonia or nitrogen levels after exposure to exogenous ammonia
has been reported (U.S. Department of Health and Human Services,
2014). Due to the rapid clearance of ammonia from the body or its
metabolization to compounds found endogenously at appreciable
levels, ammonia is not a suitable biomarker of exposure in the
context of the assessment of a candidate MRTP such as THS 2.2.
In total, 16 HPHCs were evaluated to assess exposure reduction
in the THS group compared to the CC and SA groups (Table 1).
In addition, biomarkers of exposure to nicotine (nicotine and
cotinine in plasma and nicotine equivalents measured in 24-h
urine: free nicotine, nicotine-glucuronide, free cotinine, cotinine-
glucuronide, free trans-3’-hydroxycotinine, and trans-3’-hydrox-
ycotinine-glucuronide) were also measured to assess nicotine up-
takewhen smokers switched toTHS 2.2 use compared to continued
CC smoking.
The biomarkers of exposure were assessed in blood, or 24-h
urine samples. Creatinine was also measured in 24-h urine for
adjustment of the concentration of all urinary biomarkers of
exposure. With the exception of COHb and o-toluidine (o-tol), all
biomarkers of exposure were determined by liquid
chromatography-tandem mass spectrometry. COHb and creatinine
were measured by spectrophotometry, and o-tol was measured by
gas chromatographyemass spectrometry. All laboratory analyses
were carried out using validated methods at Celerion Laboratories
(Lincoln, NE, USA and Zurich, Switzerland) except for COHb, which
was measured at Synevo Central Lab Sp. z o.o. (Warsaw, Poland).
All bioanalytical assays used were validated and all assays
conducted by Celerion Laboratories met the requirements of the
FDA Guidance to Industry: Bioanalytical Method Validation (FDA(Food and Drug Administration), 2001). Details on the bio-
analytical methods conducted at Celerion Laboratories are reported
in a data in brief (Haziza et al., 2016).
2.7. Cytochrome 1 A2 activity
Because CYP1A2 is an enzyme inducible by polycyclic aromatic
amines (PAH), a group of carcinogens found in cigarette smoke
(Butler et al., 1992), CYP1A2 activity was measured in this study as
an indicator of exposure. Cytochrome P450 (CYP) 1A2 enzymatic
activity was measured on Day 0 and on Day 5. It was based on the
post-dose paraxanthine (PX) and caffeine (CAF) plasma molar
concentrations approximately 6 h (±15 min) after the intake of
coffee made from 4.2 g (±10%) regular instant coffee (Nescafe Gold
Instant; Nestle; Deutschland; CAF content: 72 mg/2 g) with
150 ml ± 10 ml water. CYP1A2 activity was assessed by measuring
PX and CAF concentrations and calculating the PX/CAF molar
metabolic ratio (Faber and Fuhr, 2004).
2.8. Urine mutagenicity test
The urine mutagenicity test, the Ames test (Ames et al., 1975),
was assessed at baseline and Day 5 to provide an estimate of the
mutagenic load of urine samples from subjects exposed or not to
HPHCs (Gregg et al., 2013). The bacterial strain Salmonella typhi-
murium YG1024, a derivative of the original T98 strain used by
Ames, was used, in presence of the metabolic activator S9, as it was
shown to be more sensitive to mutagenicity of tobacco smoke
(Einisto et al., 1990). The assay was run in accordance with the
“OECD guideline for testing of chemicals: bacterial reverse muta-
tion test “ (OECD (Organization for Economic Co-operation and
Development) 1997)”.
2.9. Product use and human pufﬁng topography (HPT)
CC consumption was recorded for all participants from Day 2,
and tobacco sticks were recorded from Day 1 onwards in partici-
pants randomized to the THS group. All products were dispensed
individually by the site staff at the participant's request, and
dispense of each product was documented in log-books. Smoking
abstinence for participants in the SA group was veriﬁed by CO
breath tests performed 4 times/day (CO < 10 ppm). HPT was per-
formed to measure the average puff duration, inter-puff interval,
total puff volume, average puff volume, total number of puffs, and
puff frequency for each CC used at baseline in all participants, and
on Days 1 and 4, in both the CC and THS groups. HPTwas performed
using the HPT SODIM® device, model SPA/M (SODIM® Instrumen-
tation, Fleury les Aubrais, France).
The sample holders for the HPT Sodim® Device were speciﬁcally
designed for compatibility with THS2.2 and the HPT Sodim® Device
and sample holder were validated, according to our internal Quality
Management System, to ensure that measurements performed
with the device and sample holder are accurate and repeatable.
Pufﬁng topography was only assessed in subjects who smoked CCs
that were compatible with the HPT device. Therefore, users of slim
CCs were excluded from HPT assessments.
2.10. Subjective effects of smoking
The subjective effects of smoking were assessed using self-
reported questionnaires that had been validated in the local lan-
guage. Nicotine dependence was assessed at the Screening Visit
using the revised version of the Fagerstr€om Test for Nicotine
Dependence (FTND) (Fagerstr€om et al., 2012). Product evaluation
was performed using the modiﬁed Cigarette Evaluation
Table 1
List of biomarkers of exposure and corresponding harmful and potentially harmful constituents.
Acronym Biomarker of Exposure HPHC
Total NNALa total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Total NNN total N-nitrosonornicotine N-nitrosonornicotine (NNN)
MHBMA monohydroxybutenyl mercapturic acid 1,3-butadiene
3-HPMA 3-hydroxypropylmercapturic acid acrolein
S-PMA S-phenylmercapturic acid benzene
COHb carboxyhemoglobin 1 carbon monoxide
Total 1-OHPb total 1-hydroxypyrene pyrene
Total-3-OH-B[a]P 3-hydroxy-benzo(a)pyrene benzo(a)pyrene
4-ABP 4-aminobiphenyl (4-ABP) 4-aminobiphenyl
1-NA 1-aminonaphthalene (1-NA) 1-aminonaphthalene
2-NA 2-aminonaphthalene 2-aminonaphthalene
o-tol o-toluidine o-toluidine
CEMA 2-cyanoethylmercapturic acid acrylonitrile
HEMA 2-hydroxyethylmercapturic acid ethylene oxide
3-HMPMA 3-hydroxy-1-methylpropylmercapturic acid crotonaldehyde
S-BMA S-benzylmercapturic acid toluene
Biomarkers of exposure; matrix is 24 h urine if not otherwise stated. Other matrices; 1 ¼ blood. HPHC ¼ harmful or potentially harmful smoke constituent.
a Total NNAL was determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridy1)-1-butanol and its O-glucuronide conjugate.
b Total 1-OHP was determined as the molar sum of 1-hydroxypyrene and its glucuronide and sulfate conjugates.
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participants, and from Days 1e5 in the THS and CC groups. The
following domains of the mCEQ were evaluated: Smoking Satis-
faction (satisfying, tastes good, and enjoyment of smoking); Psy-
chological Reward (calms down, makes more alert, reduces
irritability, helps concentration, reduces hunger); Aversion (dizzi-
ness, nausea); Enjoyment of Respiratory Tract Sensations (single-
item assessment); and Craving Reduction (single-item assessment).
The urge-to-smoke, which evaluates how smoking is perceived as
rewarding and is perceived as providing relief from the urge to
smoke, was assessed in all participants on a daily basis fromDay1
to Day 5 using the 10-item brief version of the Questionnaire of
Smoking Urges (QSU-brief) (Cox et al., 2001).2.11. Adverse events, medical history, and concomitant medication
Safety assessment included AEs, SAEs, THS2.2 malfunctions and
misuse, vital signs, electrocardiography, spirometry, clinical
chemistry, hematology, urinalysis, physical examinations, and use
of concomitant medications. AEs were recorded from the signing of
the informed consent form until the end of the study (end of the
safety follow-up period). AEs, concomitant diseases, and medical/
surgical history were coded using the Medical Dictionary for Reg-
ulatory Activities (MedDRA version 16.0). Prior and concomitant
medications were coded according to the World Health Organiza-
tion enhanced drug dictionary (Version Q1 2013) (Uppsala
Monitoring Centre, 2012).3. Results
3.1. Participant disposition and characteristics
The study site screened 329 subjects. 160 were screen failures,
169 tried the THS2.2 during the product test, 9 subjects were
enrolled but not randomized; 8 for “abnormal” assessments and 1
for poor vein conditions. (Fig. 2).
A total of 160 participants were randomized, with 80, 41, and 39
participants in the THS, CC, and SA groups, respectively. All of the
randomized participants completed the study, except for one
participant in the THS groupwho voluntarily withdrew. There were
nomarked differences in the age, body mass index, andmean FTND
total scores among the three groups. Half of the participants (49.7%)
were classiﬁed as showing moderate nicotine dependenceaccording to the FTND questionnaires. The three groups were also
comparable in terms of the distributions of sex and daily cigarette
consumption. Most of the participants smoked cigarettes with an
ISO tar yield of 6e8mg. In each ISO tar yield category, subjects were
comparably distributed between the THS, CC, and SA groups
(Table 2).3.2. Number of tobacco sticks and CCs used daily
In the THS group, the mean ± SD number of tobacco sticks used
daily initially decreased from the number of CCs smoked at baseline
(16.0 ± 3.5) to Day 1 (14.9 ± 6.1) and then increased between Day 2
(17.3 ± 6.3) and Day 5 (20.7 ± 8.1). The number of tobacco sticks
used from Day 2 onwards was greater than the number of CCs
smoked at baseline. The mean number of CCs consumed daily
initially decreased between baseline (16.2 ± 4.1) and Day 1
(14.5 ± 3.6), but then increased by Day 5 (16.6 ± 3.8) to the baseline
level. During the study period, participants in the THS group
consumed a greater number of tobacco sticks than the number of
CCs smoked by participants in the CC group (Table 3).3.3. Biomarkers of exposure
Levels of biomarkers of exposure to 16 HPHCs and to nicotine
are presented in the data in brief Table 1 (Haziza et al., 2016) at
Baseline and at Day 5 for the THS, CC and SA groups (all urinary
biomarkers of exposure are expressed as concentrations adjusted to
creatinine). At baseline, the levels of biomarkers of exposure were
comparable in all three groups, except for MHBMA, which was
slightly higher in the CC group, but comparable between the THS
and SA groups. On Day 5, at the end of the exposure period, the
levels of ﬁfteen biomarkers of exposure (COHb, S-PMA, MHBMA, 3-
HPMA, total NNN, total NNAL, total 1-OHP, 4-ABP, 1-NA, 2-NA, o-
toluidine, CEMA; HEMA, 3-HMPMA, and total-3-OH-B[a]P) were
reduced in both THS and SA groups as compared to Baseline (Fig. 3,
data in brief, Table 2; Haziza et al., 2016). The reduction was of
similar magnitude between the THS and SA groups for each
biomarker except for total NNAL, total NNN and 3-HPMA for which
the reduction was slightly higher in SA than THS groups.
Signiﬁcant reductions in the levels of the biomarkers of expo-
sure (urinary biomarkers of exposure expressed as concentrations
adjusted to creatinine) were demonstrated in the THS group rela-
tive to the CC group on Day 5, with percent reductions of 77% for
Fig. 2. Disposition of cases. Description of participants' disposition in the course of the study. Abbreviations: CC ¼ conventional cigarette use group; SA ¼ smoking abstinence
group; THS2.2 ¼ Tobacco Heating System 2.2 use group.
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Furthermore, reductions of 56% in Total NNAL, 76% in Total NNN,
56% in Total 1-OHP, 85% in 4-ABP, 96% in 1-NA, 88% in 2-NA, 58% in
o-toluidine, 87% in CEMA, 68% in HEMA, 77% in 3-HMPMA, and 72%
in total-3-OHeB[a]P were observed in the THS group relative to the
CC group (Table 4). Comparable levels of reduction were obtained
when the urinary biomarkers of exposure were expressed as
quantity excreted over 24 h (data in brief, Table 3; Haziza et al.,
2016).
The levels of S-BMA, a biomarker of exposure to toluene, were
comparable across all 3 study groups throughout the studyTable 2
Demographic characteristics by group, at baseline.
Variable and statistic THS
N ¼ 80
CC
N ¼ 41
SA
N ¼ 39
Age (years)
Mean ± SD 35.4 ± 9.40 32.6 ± 10.06 33.6 ± 11.51
Range 22 to 59 21 to 59 21 to 60
BMI (kg/m2)
Mean ± SD 24.46 ± 3.034 25.80 ± 3.228 24.81 ± 2.505
Range 18.9 to 31.6 18.8 to 31.8 20.3 to 31.6
Sex, n (%)
Male 39 (48.8%) 21 (51.2%) 20 (51.3%)
Female 41 (51.3%) 20 (48.8%) 19 (48.7%)
Daily CC consumption, n (%)
10 to 19 cigarettes 41 (51.3%) 21 (51.2%) 19 (48.7%)
>19 cigarettes 39 (48.8%) 20 (48.8%) 20 (51.3%)
ISO tar yield, n (%)
1e5 mg 6 (7.5%) 7 (17.1%) 4 (10.3%)
6e8 mg 43 (53.8%) 26 (63.4%) 29 (74.4%)
9e10 mg 31 (38.8%) 8 (19.5%) 6 (15.4%)
FTND total scorea
Mean ± SD 5.0 ± 2.02 5.1 ± 1.83 5.5 ± 1.93
Range 1 to 9 1 to 9 1 to 9
a Calculated on a different N; THS ¼ 76, CC ¼ 40, SA ¼ 38. Abbreviations:
CC ¼ combustible cigarette use group; SA ¼ smoking abstinence group;
THS ¼ Tobacco Heating System 2.2 use group; SD ¼ standard deviation; BMI ¼ body
mass index; FTND ¼ Fagerstr€om Test for Nicotine Dependence, ISO ¼ international
standardization organization.including at baseline (data in brief, Tables 1 and 2; Haziza et al.,
2016). Despite the fact that S-BMA is suitable to detect toluene in
environmental and occupational studies (Lovreglio et al., 2010), in
this study it could not discriminate between smokers and smokers
who are abstinent from smoking, an observation reported by other
authors as well (Imbriani et al., 1999; Schettgen et al., 2008).3.4. Exposure to nicotine
Exposure to nicotine was comparable for the THS and CC groups
throughout the study period. In the THS and CC groups, geometric
mean NEQ values increased from baseline (9.01 mg/g creat for THS
and 8.69 mg/g creat for CC) to Day 1 (9.19 mg/g creat for THS andTable 3
Daily product consumption; number of tobacco sticks and cigarettes.
Visit day THS
N ¼ 80
CC
N ¼ 41
Baseline use
Mean ± SD 16.0 ± 3.45 16.2 ± 4.05
Range 9e33 10e32
Day 1
Mean ± SD 14.9 ± 6.14 14.5 ± 3.63
Range 5e50 6e22
Day 2
Mean ± SD 17.3 ± 6.25 15.1 ± 3.79
Range 6e40 8e24
Day 3
Mean ± SD 18.2 ± 5.94 14.9 ± 3.49
Range 6e38 8e22
Day 4a
Mean ± SD 18.5 ± 6.69 14.3 ± 3.43
Range 9e50 8e21
Day 5a
Mean ± SD 20.7 ± 8.09 16.6 ± 3.79
Range 9e60 10e26
a Calculated on a different N; THS¼ 79. Abbreviations: CC¼ combustible cigarette
use group; THS ¼ Tobacco Heating System 2.2 use group; SD ¼ standard deviation.
Fig. 3. Disposition of cases. Relative change from baseline were calculated from the geometric means values for each biomarker of exposure. # for total NNN, the median change
from Baseline is reported. CC: combustible cigarette; SA: smoking abstinence.
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(8.66 mg/g creat for THS and 8.91 mg/g creat for CC), to progres-
sively increase to Day 5 (10.60 mg/g creat) for THS and (9.76 mg/g
creat) for CC. The values on Day 5 correspond to percent changes
from baseline of 22.95% and 14.78% for the THS and CC groups,
respectively (Table 4). The NEQ levels in the THS groupwere similar
to those of the CC group on Day 5, with a THS vs. CC ratio of 104.9%
(95% CI: 92.0; 119.6). Similar results were obtained with plasma
nicotine and cotinine. On Day 5, the geometric mean (95% CI)
plasma nicotine (ng/mL) concentrations were similar in the THS
and CC groups and were 20.7 (17.46; 24.62) vs. 19.0 (16.52; 21.87)
for CC, and plasma cotinine (ng/mL) was 240.0 (211.30; 272.58) vs.
219.7 (190.21; 253.83) for CC.3.5. Cytochrome 1A2 activity
At baseline, CYP1A2 activity was similar in all three groups. On
Day 5, the LS mean CYP1A2 activity following coffee intake was
91.35% and 124.95% in the THS and CC groups respectively with LS
mean difference THS-CC of 33.60% (95% CI: 40.59, 26.61). The
activity was comparable between the THS and the SA groups (LS
mean difference THS-SA: 1.99% (95% CI: 9.10, 5.12).3.6. Urine mutagenicity test
At Baseline, median Ames mutagenicity test values were 19681
Rev/24 h (min: 0; max: 107,250 Rev/24 h) for THS, 22540 Rev/24 h
(min: 3060; max: 113,620 Rev/24 h) for the SA arms, and 15,775
Rev/24 h (min:0; max: 72,216 Rev/24 h) for the CC arm. On Day 5, in
the THS and SA arms, the median decrease from baseline for Ames
mutagenicity test values was approximately 57% (8823 Rev/24 h;
min:0; max: 39,600 Rev/24 h) and 62% (7437 Rev/24 h; min:0;
max: 65,400 Rev/24 h), respectively, while in the CC arm, median
values increased from Baseline by approximately 29% (21,689 Rev/
24 h; min:0; max: 63,840 Rev/24 h).3.7. Human pufﬁng topography
The baseline values for each assessed HPT parameter were
generally comparable in the THS and CC groups while subjects were
smoking their own preferred brand of CC and remained unchanged
in the CC group between Baseline and Day 1, and between Day 1
and Day 4.
In the THS group, values for total puff volume, average puff
volume, and total number of puffs were within the same ranges
from Baseline to Day 4. In contrast, average puff duration, total puff
Table 4
Biomarkers of exposure, ratios of THS relative to CC.
Biomarkers Ratioa % and CI THS (N ¼ 81)/CC (N ¼ 41)
NEQ (mg/g creat) 104.9 (92.0; 119.6)
Nicotineb,c (ng/mL) 112.9(91.3; 139.5)
Cotinineb,c(ng/mL) 111.0 (90.8; 135.7)
Total NNAL (pg/mg creat) 43.5 (39.3; 48.2)
Total NNN (pg/mg creat) 24.1 (17.7; 32.8)
COHbc (%) 23.5 (22.0; 25.0)
MHBMA (pg/mg creat) 8.4 (6.8; 10.2)
3-HPMA (ng/mg creat) 41.6 (37.7; 46.0)
S-PMA (pg/mg creat) 6.0 (5.2; 6.9)
Total 1-OHP (pg/mg creat) 44.3 (39.8; 49.4)
4-ABP (pg/mg creat) 14.9 (12.8; 17.4)
1-NA (pg/mg creat) 3.7 (3.1; 4.5)
2-NA (pg/mg creat) 11.5 (10.0; 13.3)
o-tol (pg/mg creat) 41.7 (36.0; 48.3)
CEMA (ng/mg creat) 13.2 (11.5; 15.0)
HEMA (pg/mg creat) 32.0 (27.1; 37.8)
3- HMPMA (ng/mg creat) 22.5 (20.1; 25.3)
Total 3-OH-B[a]P (fg/mg creat) 27.5 (23.2; 32.6)
a Ratio: Geometric least squares mean ratio (%) and conﬁdence intervals from an
ANCOVA model conducted on log-transformed Day 5 values with log-transformed
baseline value (urinary biomarker of exposure expressed as concentration
adjusted to creatinine), study arm, sex and CC consumption reported at screening as
ﬁxed effect factors (THS/CC) on Day 5.
b Weighted average concentration over 24 h (Cavg); also for nicotine and cotinine
the ratio is calculated on the weighted average concentration over 24 h.
c Measured between 8:00 PM and 10:00PM. Abbreviations: CI ¼ Conﬁdence in-
terval. CC ¼ combustible cigarette group; THS ¼ Tobacco Heating System 2.2 group.
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baseline to Day 1 and then to Day 4.
The average puff durationwas about 26% and 32% longer relative
to CC on Day 1 and Day 4 respectively, with values of 2.0s for THS vs
1.6s for CC on Day 1 and 2.1s for THS vs 1.6s for CC on Day 4. The
total puff duration was about 36% and 37% longer relative to CC onTable 5
Human pufﬁng topography parameters per cigarette in THS and CC groups.
Variable and Day THS
N ¼ 56
Total Puff Volume (mL)
Baselinea 774.6 (774.7; 819.6)
Day 1b 792.8 (725.3; 860.3)
Day 4c 810.5 (752.4; 868.7)
Average Puff Volume (mL)
Baselinea 53.4 (49.8; 57.1)
Day 1b 50.6 (46.2; 55.0)
Day 4c 52.9 (84.7; 57.1)
Average Puff Duration (s)
Baselinea 1.6 (1.5; 1.8)
Day 1b 2.0 (1.8; 2.2)
Day 4c 2.1 (1.9; 2.4)
Total Puff Duration (s)
Baselinea 23.8 (22.1; 25.5)
Day 1b 32.0 (29.5; 34.7)
Day 4c 33.2 (30.1; 36.4)
Total Number of Puffs
Baselinea 15.1 (14.1; 16.1)
Day 1b 16.2 (15.4; 17.0)
Day 4c 15.7 (15.1; 16.5)
Puff frequency (puffs/min)
Baselinea 3.5 (3.2; 3.9)
Day 1b 5.0 (4.7; 5.4)
Day 4c 5.2 (4.9; 5.6)
All values are Mean and 95% CI, except THS/CC mean ratio (%); adjusted geometric lea
Abbreviations: CC ¼ combustible cigarette use group; THS ¼ Tobacco Heating System
a Calculated on a different N; THS ¼ 56.
b Calculated on a different N; THS ¼ 79.
c Calculated on a different N; THS ¼ 78.Day 1 and Day 4 respectively. The puff frequency was about 31%
higher and 32% higher on Day 1 and Day 4 respectively for THS vs
CC (Table 5).3.8. Subjective effects of smoking
3.8.1. Modiﬁed cigarette evaluation questionnaire subscales
The mCEQ average results of the whole 5 day exposure period
showed that, adjusted for baseline, smoking satisfaction, craving
reduction, enjoyment of respiratory tract sensation and psycho-
logical reward, were lower for participants who switched toTHS 2.2
use compared to participants who continued to smoke CC, with
differences of 1.26,-1.12, 1.00, 0.72, respectively with 95% CIs
excluding 0. Aversion was comparable between THS and CC
(Table 6).3.8.2. Urge-to-smoke symptoms (QSU-brief)
The mean urge-to-smoke total scores were comparable in all
groups at baseline, with scores of 3.69, 3.49, and 3.49 in the THS, CC,
and SA groups, respectively. The mean urge-to-smoke total scores
remained stable and were comparable between the THS and CC
groups throughout the study, ranging from 2.9 to 3.3 in the THS
group, and from 3.2 to 3.5 in the CC group. Considering all time-
points of assessment, the QSU-brief total score was comparable
between the THS and CC groups with the difference between THS
and CC of 0.3 (95% CI: 0.75, 0.12) (Fig. 4).
In the SA group, as expected, the urge-to-smoke total score
increased signiﬁcantly from 3.49 at baseline to 5.3 on Day 1, cor-
responding to an increase of 1.8 (95% CI: 4.82, 5.76). From Day 3
onwards, the urge-to-smoke started to decrease but remained
above the baseline value on Day 5. The LS mean difference in QSU-
brief total score between the THS group and the SA group was 1.8
(95% CI: 2.27, 1.39).CC
N ¼ 27
THS/CC Ratio (%)
N ¼ 83
899.3 (764.4; 1034.2)
819.2 (728.8; 909.7) 109.5 (94.7; 126.7)
845.8 (757.2; 93,452) 105.2 (92.5; 119.7)
53.6 (46.8; 60.5)
49.2 (43.7; 54.8) 101.5 (90.6; 113.)
49.4 (44.2; 54.6) 105.5 (95.5; 116.5)
1.5 (1.3; 1.8)
1.5 (1.3; 1.8) 126.0 (115.3; 137.9)
1.5 (1.3; 1.8) 132.2 (120.2; 145.5)
25.9 (23.2; 28.6)
26.2 (23.2; 29.3) 136.0 (119.8; 154.5)
26.6 (23.6; 29.8) 137.3 (119.3; 158.1)
17.1 (15.3; 19.0)
17.2 (15.3; 19.1) 103.0 (94.2; 112.7)
17.7 (15.9; 19.7) 97.1 (89.4; 105.6)
4.4 (3.7; 5.2)
4.6 (3.9; 5.3) 131.3 (116.9; 147.5)
4.8 (4.0; 5.7) 132.3 (118.2; 148.1)
st squares means ratio, and 95% conﬁdence intervals.
2.2 use group.
Table 6
Analysis of change from baseline in mCEQ.
Subscale THS
N ¼ 79
CC
N ¼ 41
(THS  CC) difference
N ¼ 120
Smoking Satisfaction 1.51 0.25 1.26 (1.68, 0.85)
Aversion 0.15 0.10 0.25 (0.04, 0.46)
Craving Reduction 1.53 0.41 1.12 (1.58, 0.66)
Enjoyment of Respiratory Tract Sensation 1.23 0.23 1.00 (1.36, 0.64)
Psychological Reward 1.13 0.41 0.72 (1.06, 0.39)
Adjusted LS means and 95% CIs from an ANCOVAmodel with study arm, sex, CC consumption reported at Screening, day, and study arm*day ﬁtted as ﬁxed effect factors
with baseline ﬁtted as a covariate. Day ﬁtted as a repeated factor. Abbreviations: CC ¼ combustible cigarette use group; THS ¼ Tobacco Heating System 2.2 use group.
CI ¼ conﬁdence interval; mCEQ ¼ modiﬁed cigarette evaluation questionnaire.
Fig. 4. Questionnaire on smoking urges mean total score. Comparison of the relief from smoking total scores derived from the QSU-brief. Results are presented as the mean (95%
conﬁdence interval). Abbreviations: CC ¼ combustible cigarette use group; SA ¼ smoking abstinence group; THS ¼ Tobacco Heating System 2.2 use group.
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The safety population consisted of 169 participants. This
included all 160 randomized participants and 9 individuals who
were enrolled and exposed to THS 2.2 from the product test on
Day 2 but were not randomized. Overall, 227 AEs were reported
by 112/169 participants. There were no SAEs and none of the ran-
domized subjects were discontinued from the study because of an
AE. Most of the AEs were classiﬁed as mild or moderate in severity.
Only one severe AE was reported. This severe AE occurred in the CC
group and was not considered to be related to CC use or to study
procedures. The incidence of AEs with frequency >5% were similar
in the THS (50/80 participants [62.5%]), CC (29/41 [70.7%] partici-
pants), and SA (24/39 [61.5%]) groups. The 9 participants who were
exposed, but not randomized, reported at least one AE each. The
most frequent AEs in the THS and CC groups were headache,
oropharyngeal pain, syncope, polyuria, and spirometry abnormal.
The most frequent AEs in the SA group were headache, back pain,
inﬂuenza-like illness, spirometry abnormal, abdominal distension,
hypertriglyceridemia, polyuria, hypertension, and vertigo. Adescriptive summary of AE with frequency > than 5% is provided in
Table 7.
4. Discussion
The present study demonstrated that switching to THS 2.2 leads
to a reduction in COHb, S-PMA, MHBMA, and 3-HPMA, 4 bio-
markers of exposure to the following HPHCs: carbon monoxide,
benzene, 1e3 butadiene, and acrolein, respectively, after 5 days of
use in a controlled setting relative to smoking CC. Furthermore,
reduction in an additional 11 biomarkers of exposure was observed
in subjects using THS 2.2 for 5 days compared to subjects
continuing to smoke CC. Biomarkers of exposure to HPHCs were
assessed and compared between THS 2.2, the participant's own
brand of non-menthol CCs, and smoking abstinence. Overall, the
reduction in exposure to HPHCs assessed in this study was com-
parable to that observed in the smoking abstinence group.
The reduction of the 15 biomarkers of exposure in the THS group
vs the CC group ranged from 56% to 96%. For the biomarkers of
exposure which were measured, a similar magnitude of reductions
Table 7
Adverse events.
Adverse Events THS CC SA Overall Safety
(N ¼ 80) (N ¼ 41) (N ¼ 39) (N ¼ 169)
Total AEs (%) 50 (62.5%) 29 (70.7%) 24 (61.5%) 112 (66.3%)
AEs (%) over 5%
Headache 24 (30.0%) 16 (39.0%) 13 (33.3%) 56 (33.1%)
Syncope 6 (7.5%) 4 (9.8%) 0 10 (5.9%)
Spirometry abnormal 4 (5.0%) 3 (7.3%) 2 (5.1%) 12 (7.1%)
Abdominal distension 0 0 2 (5.1%) 2 (1.2%)
Oropharyngeal pain 7 (8.8%) 3 (7.3%) 0 10 (5.9%)
Hypertriglyceridaemia 3 (3.8%) 2 (4.9%) 2 (5.1%) 7 (4.1%)
Polyuria 6 (7.5%) 4 (9.8%) 2 (5.1%) 12 (7.1%)
Back pain 3 (3.38%) 2 (4.9%) 3 (7.7%) 8 (4.7%)
Hypertension 1 (1.3%) 1 (2.4%) 2 (5.1%) 6 (3.6%)
Inﬂuenza like illness 0 1 (2.4%) 3 (7.7%) 4 (2.4%)
Vertigo 3 (3.8%) 0 2 (5.1%) 5 (3.0%)
Description of total adverse events occurred during the study and summary of
adverse events with frequency > than 5%. Terms coded using MedDRA® version
16.0. Abbreviations: N ¼ number of subjects Percentages were calculated using the
N of subjects in the column headers. AE¼ adverse event; CC¼ combustible cigarette
use group; SA ¼ smoking abstinence group; THS ¼ Tobacco Heating System 2.2 use
group; Overall Safety ¼ Participants exposed at least once to THS 2.2.
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switched for 5 days to smoking abstinence (Theophilus et al., 2015)
as well as in other studies on smoking abstinence (Carmella et al.,
2012; Sarkar et al., 2008).
In 2012, the US FDA published an abbreviated list of 20 HPHCs,
fromwhich 18 constituents in cigarette smoke were recommended
to be measured and reported (Food and Drug Administration,
2012a,2012b). The present study assessed 16 HPHCs, including 14
of the HPHCs requested by the FDA and 9 HPHCs that the World
Health Organization recommended to be lowered in cigarette
smoke (FDA (Food and Drug Administration), 2012b; WHO Study
Group et al., 2008). We also measured exposure to pyrene (as to-
tal 1-OHP), an indicator of polycyclic aromatic hydrocarbon, and
exposure to the aromatic amine o-toluidine (o-tol), as both are
strong carcinogens, associated with colon and bladder cancer (IARC
(International Agency for Research on Cancer), 2012) as well as
exposure to ethylene oxide (HEMA), because inhalation of ethylene
oxide is irritating tomucousmembranes including those associated
with the respiratory system (U.S. Department of Health and Human
Services et al., 1990). Four HPHCs present on the FDA's list;
ammonia, formaldehyde, acetaldehyde and isoprene, were not
measured. Isoprene was not considered because of the high
amount of endogenous production (OECD (Organization for
Economic Co-operation and Development), 2005), and because of
the very short half-life. Isoprene levels in humans have not been
reported as being reliable to distinguish smokers from non-
smokers (Euler et al., 1996). Acetaldehyde was not measured
because of the lack of an established biomarker of exposure.
Because of the various sources of exposure to formaldehyde,
including environmental exposure, its short half-life and lack of a
speciﬁc metabolite, as well as the lack of a robust, simple and
validated method suitable for a clinical setting, exposure to form-
aldehyde was not measured in this study.
The study showed that switching from CCs to THS 2.2 for 5 days
reduced biomarkers of exposure to HPHCs to values generally lower
than 50% or more, and approached exposure reduction observed in
the SA group. Although the magnitude of reduction for total NNAL,
total NNN, 3-HPMA, and 3-HMPMA, were slightly lower in the THS
group relative to SA, the levels found in both the THS and SA group
were considerably lower when compared to the levels of bio-
markers of exposure found in the CC group. For total NNAL, total
NNN, and 3-HMPMA, it is likely that these low levels can bedetected in urine of THS groups because of the direct transfer of
NNN, NNK, and crotonaldehyde which is reported to occur when
tobacco is heated at low temperature between 100 C and 200 C
(Forster et al., 2015; Rodgman and Perfetti, 2013). For 3-HPMA, it is
described in the literature that it could be formed from the
degradation of glycerin (Qadariyah et al., 2011). The exposure
reduction observed in the SA group was overall preserved in par-
ticipants using THS 2.2. In conclusion, the elimination of combus-
tion provided by the heat-not-burn technology, effectively
minimized the exposure to HPHCs usually found in CC smokers.
CYP1A2 catalyzes many of the reactions involved in the meta-
bolism of low therapeutic-index drugs and synthesis of cholesterol,
steroids, and other lipids (Kroon, 2007). More importantly, CYP1A2
enzymes are monooxygenase involved in the activation of carci-
nogenic heterocyclic and aromatic amines. These active metabo-
lites (N-acetoxy derivatives) can react with DNA to form covalent
heterocyclic amine-DNA adducts, which are strong carcinogens
associated with colon and bladder cancer (Matsuda et al., 2015;
Gunes and Dahl, 2008; MacLeod et al., 1997). In addition, the
CYP1A2 expression itself is induced to a large extent by PAH which
are found in cigarette smoke (Butler et al., 1992). The 72% reduction
of total-3-OHeB[a]P, a PAH; after 5 days of THS use compared to CC,
likely explains the ~30% reduction in CYP1A2 activity in the THS
group, similar to the reduction in the SA group. Thus, the reduction
in enzymatic activity of CYP1A2 when subjects use THS for 5 days,
as observed upon smoking cessation, is not only an additional in-
dicator of reduced exposure to HPHCs but also reﬂects a favorable
biological change associated with the lower level of active and
carcinogenic metabolites. This may support the potential of THS to
lower the risk of tobacco-related diseases.
In line with these data from human exposure, in a previously
reported study conducted in Apoe/mice for 8 months, cigarette
smoke induced both gene and protein expression of CYP1A2 in the
liver (the main site of CYP1A2 expression), while exposure to THS
aerosol did not. Furthermore, switching to THS aerosol following
cigarette smoke exposure lead to a reduction in CYP1A2 gene and
protein expression to levels approaching those of cessation (Lo
Sasso et al., 2016).
Along with these results, the similar magnitude of decrease in
mutagenic load of urine samples from subjects in both THS and SA
groups, add to the evidence of reduced exposure to HPHCs. The
high variability of this test as exhibited by the large range covered
by theminimum andmaximal values for eachmedian estimate is in
agreement with other published data (Miura et al., 2015; Roethig
et al., 2008; Sakaguchi et al., 2014; Sarkar et al., 2010). This high
variability is well known and could be explained by the high
sensitivity of the test to factors other than tobacco smoke such as
diet, but also by the complexity of the assay as a cellular test.
The reduction in exposure to HPHCs was not found to be related
to differences in product consumption, as daily product use
increased in the THS group and was overall higher than in the CC
group. It was anticipated that switching to THS 2.2 would require a
period of adaptation for the participants concerned as the THS
users were using a new product with a different nicotine yield,
taste, and sensory characteristics compared to their own brand of
CC. The topography and consumption results, as well as the results
observed for subjective effects measures support this interpreta-
tion. Adjustment of individuals to the new product occurred during
the study, not only through an increase in daily tobacco stick use,
compared to CC daily consumption, but also through changes in
HPT parameters. In summary, the HPT assessment indicated that
participants using THS 2.2, had a comparable total puff volume,
took a similar number of puffs of a similar volume, but adapted to
the product by taking longer puffs with an increased average puff
duration and total puff duration, while shortening the inter-puff
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smoking CC. These changes in product use behavior allowed par-
ticipants in the THS group to titrate nicotine closely to their base-
line levels before the product switch and to comparable levels as
observed in the CC group at the end of the 5-day exposure period.
Whilst the urge-to-smoke scores were comparable between
groups throughout the study, the subscales of mCEQ showed that
craving reduction, enjoyment of respiratory tract sensation, psy-
chological reward, and smoking satisfaction were all lower for THS
2.2 compared to CC throughout the 5 days of exposure. By contrast,
aversion was higher for THS than CC from Day 1 (the ﬁrst Day of
switching) with the difference between the two groups becoming
progressively smaller up to Day 5. However, it is likely that the
duration of the study was not sufﬁcient to show the completion of
an adaptation process and the study should be taken with the
limitations inherent to the design.
One limitation of this 5 day study is that it could not capture a
completed reduction of the biomarkers of exposure with a long
half-life such as Total NNAL which exhibit a half-life of about 10e18
days (Goniewicz et al., 2009; Hecht et al., 1999). Nevertheless, the
reduction of 56% in the levels of Total NNAL, a tobacco speciﬁc-
nitrosamine for which an association with lung cancer is demon-
strated in smokers, is extremely promising as one can expect even
further decline, considering the long half-life of this metabolite,
under prolonged use of THS. Finally, the conﬁnement setting limits
the generalizability of the results to real-world conditions of use
and the interpretation of subjective effects related to THS 2.2.
Indeed, the adaptation of smokers to a new tobacco product is
likely to take longer than 5 days.
For these reasons, longer studies in ambulatory settings need to
be conducted to evaluate how the reductions would be sustained
with less control over product use. Yet this study allowed an
assessment of comparative exposure under optimal conditions, by
its randomized controlled design, the ad libitum product use in a
conﬁned setting, and by avoiding dual use.
A strength of the studywas that all biomarkers of exposurewere
measured in 24-h urine collection using validated methods.
Compared to partial urine or spot urine, 24-h urine collection is
considered the most accurate approach to measure excretion of the
metabolites generated from exposure to HPHCs. Furthermore the
HPHCs measured in this study cover multiple chemical classes,
toxicity grades, half-lives, gas and particulate phases, and forma-
tion temperatures, providing indication that THS 2.2 reduces
exposure to a broad spectrum of HPHCs. In conclusion, this study
showed that ad libitum use of THS 2.2 for 5 days reduced bio-
markers of exposure to 15 HPHCs as comparedwith continuing CCs,
and that decreases in the THS group approached those observed
after smoking abstinence. The observed reductions in biomarkers
of exposure to HPHCs occurred despite an increase in tobacco stick
use and changes in pufﬁng behavior compared with CC use.
Although the scores for product evaluation and the sensory expe-
rience for THS 2.2 were lower than those for CCs, urge-to-smoke
reduction and aversion reduction over time indicate that THS 2.2
offers a suitable alternative to CCs, although it may take longer than
5 days to complete adaptation to THS 2.2. THS 2.2 was well toler-
ated and had a safety proﬁle comparable with CCs.Conﬂict of interest statement
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